These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18957472)

  • 1. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
    Regieli JJ; Jukema JW; Grobbee DE; Kastelein JJ; Kuivenhoven JA; Zwinderman AH; van der Graaf Y; Bots ML; Doevendans PA
    Eur Heart J; 2008 Nov; 29(22):2792-9. PubMed ID: 18957472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
    Carlquist JF; Muhlestein JB; Horne BD; Hart NI; Bair TL; Molhuizen HO; Anderson JL
    Am Heart J; 2003 Dec; 146(6):1007-14. PubMed ID: 14660992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
    Marschang P; Sandhofer A; Ritsch A; Fiŝer I; Kvas E; Patsch JR
    J Intern Med; 2006 Aug; 260(2):151-9. PubMed ID: 16882279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
    Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
    Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
    de Grooth GJ; Zerba KE; Huang SP; Tsuchihashi Z; Kirchgessner T; Belder R; Vishnupad P; Hu B; Klerkx AH; Zwinderman AH; Jukema JW; Sacks FM; Kastelein JJ; Kuivenhoven JA
    J Am Coll Cardiol; 2004 Mar; 43(5):854-7. PubMed ID: 14998629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
    Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
    N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
    Barter P
    Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CETP TaqIB polymorphism is associated with the risk of sudden death in type 2 diabetic patients.
    Porchay-Baldérelli I; Péan F; Bellili N; Jaziri R; Marre M; Fumeron F;
    Diabetes Care; 2007 Nov; 30(11):2863-7. PubMed ID: 17666459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic variation of the cholesterol ester transfer protein gene and the prevalence of coronary artery disease. The AtheroGene case control study].
    Blankenberg S; Tiret L; Bickel C; Schlitt A; Jungmair W; Genth-Zotz S; Lubos E; Espinola-Klein C; Rupprecht HJ
    Z Kardiol; 2004; 93 Suppl 4():IV16-23. PubMed ID: 15085362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cholesteryl ester transfer protein -629C > A polymorphism with high-density lipoprotein cholesterol levels in coronary artery disease patients.
    Tanrikulu S; Ademoglu E; Gurdol F; Mutlu-Turkoglu U; Bilge AK; Nisanci Y
    Cell Biochem Funct; 2009 Oct; 27(7):452-7. PubMed ID: 19784962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer.
    Dullaart RP; Borggreve SE; Hillege HL; Dallinga-Thie GM
    Scand J Clin Lab Invest; 2008; 68(2):99-105. PubMed ID: 17852818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesteryl ester transfer protein B1B1 genotype as a predictor of coronary artery disease in Taiwanese with type 2 diabetes mellitus.
    Hsieh MC; Tien KJ; Chang SJ; Lo CS; Hsin SC; Hsiao JY; Hsu SC; Liang HT; Chen HC; Shin SJ; Lin SR
    Metabolism; 2007 Jun; 56(6):745-50. PubMed ID: 17512305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
    Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
    J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
    Takata M; Inazu A; Katsuda S; Miwa K; Kawashiri MA; Nohara A; Higashikata T; Kobayashi J; Mabuchi H; Yamagishi M
    Clin Sci (Lond); 2006 Nov; 111(5):325-31. PubMed ID: 16822236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease.
    Blankenberg S; Rupprecht HJ; Bickel C; Jiang XC; Poirier O; Lackner KJ; Meyer J; Cambien F; Tiret L;
    J Am Coll Cardiol; 2003 Jun; 41(11):1983-9. PubMed ID: 12798569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.